NCT05118906

Pilot Study on BP1.4979 Effect on Binge Eating Disorders

A Double-blind, Placebo-controlled Pilot Trial of BP1.4979 for the Treatment of Binge Eating Disorder

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 67 (actual)
• Sponsor: Bioprojet · Academic / Other
• Sex: Female
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This pilot study is to assess the efficacy and safety of BP1.4979 15 mg BID in female patients with moderate to severe binge eating disorder (BED), as defined according to DSM-5 guidelines.

Detailed description

First clinical study to assess the effect of the BP1.4979 on BED in female patients over an 8 week-tretament period.

Conditions

• Binge-Eating Disorder

Interventions

Type	Name	Description
DRUG	BP1.4979 active drug	2 tablets 15 mg of BP1.4979 per day
DRUG	Placebo	2 tablets of placebo per day

Timeline

• Start date: 2022-03-07
• Primary completion: 2025-08-14
• Completion: 2025-08-21
• First posted: 2021-11-12
• Last updated: 2025-11-25

Locations

1 site across 1 country: France